BioNTech will make $800mn in upfront payments to Biotheus, a drugmaker based in Guangdong province, with milestone payments of up to $150mn. Uğur Şahin, chief executive of BioNTech, said the company ...

'Once you dissolve truth, democracy dissolves with it...we have never seen anything like this in the history of the country.' ...

The modern statue celebrates Alice Kan, who during the Covid pandemic was the programme manager for the fill-finish process ...

On the heels of releasing its latest financial statement, Vancouver-based biotechnology company Absci announced it has met its first milestone in its collaboration with pharmaceutical giant AstraZenec ...

AstraZeneca plans a new investment of $2 billion in the ... Novavax shares fell after the vaccine developer cut its full-year growth projections, offsetting a narrower-than-expected third-quarter loss ...

AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease ...

AstraZeneca boss Pascal Soriot (pictured)) threw his weight behind its Chinese business despite the recent arrest of its boss ...

AstraZeneca’s new U.S. spending also leaves in doubt the pharmaceutical company’s plans to invest in a vaccine site in ...

The company said it aims to expand its U.S. presence by the end of 2026. The new spending will be for a research-and-development center in Cambridge, Mass.; manufacturing plants in Maryland and Texas, ...

London-listed drugmaker AstraZeneca said its plan to invest 450 million pounds ($576.7 million) in Britain for vaccine ...

AstraZeneca chief Pascal Soriot has said a deepening criminal probe into his company’s Chinese business is being taken “very ...

AstraZeneca's £450 million investment plan for vaccine R&D in the UK is under review as discussions on governmental ...